Search results
COVID summer guide: How to navigate symptoms, variants and vaccines this season amid rising cases
Yahoo Life· 4 hours agoWho should wait and who should get vaccinated now? The CDC advises that everyone age 5 and older...
FDA advises vaccine manufacturers to make COVID-19 booster targeting KP.2 strain
ABC Action News Tampa Bay· 1 day agoThe FDA has issued an updated recommendation for the fall COVID-19 vaccine formula. "Coverage in the...
The FDA Now Wants Fall COVID Vaccines to Target KP.2—But Not All Manufacturers Can Pivot
Verywell Health via Yahoo News· 5 days agoLess than a week after telling COVID-19 vaccine manufacturers to target the JN.1 variant this fall,...
Exsilio debuts with $82M, pitching a ‘leap’ forward for genetic medicine
BioPharma Dive via Yahoo Finance· 15 hours agoIt’s led by interim CEO Tal Zaks, who was Moderna’s chief medical officer when the company...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 5 days agoFurther, Moderna confirmed it's in discussions with the U.S. government to move forward with its...
Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe
Zacks via Yahoo Finance· 4 hours agoNovavax (NVAX) seeks marketing authorization in the European Union for an updated version of its...
Summer COVID bump intensifies in L.A. and California, fueled by FLiRT variants
LA Times via AOL· 1 day agoThe new COVID FLiRT subvariants are continuing to increase their dominance, fueling a rise in Los...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. -...
CW39 NewsFix· 21 hours agoPomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA). Such investors are advised to ...
The FDA awarded a record number of review designations to mRNA vaccines in 2023
Pharmaceutical Technology via Yahoo Finance· 1 day agoThis conclusion was confirmed by the FDA approval of Moderna’s mRESVIA, an mRNA vaccine for...
Moderna shares rise as Argus lifts price target to $150 By Investing.com
Investing.com· 5 days agoThe firm's decision follows the U.S. Food and Drug Administration's (FDA) approval of Moderna's...